BioWorld

Oct. 8, 2009

View Archived Issues

MannKind Bulls, Bears Face off in Wake of Afresa Partner Delay

News that MannKind Corp. will not achieve its goal of signing a partnership this year for inhaled insulin product Afresa polarized the company's bullish backers and its bearish detractors. (BioWorld Today) Read More

Epizyme's $32M to Fuel HMTs; Nobel Winner Helps the Push

Read More

Androxal Gives Repros Relief; Proellex, Cash Troubles Loom

Read More

Allos Expands Offering, Adds $100M for Folotyn Launch Prep

Read More

MIT Biochemist, Stem-Cell Ace Among National Medal Winners

Read More

Other News To Note

Read More

Clinic Roundup

Read More